Navigation Links
Delcath Systems, Inc. Announces the Completion of Common Stock Offering
Date:7/20/2011

NEW YORK, July 20, 2011 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH) today announced it has closed its previously announced offering of 5,000,000 common shares at a price to the public of $5.05 per share.  Delcath has granted Jefferies & Company, Inc., the sole book-runner for the offering, an over-allotment option to purchase up to an additional 750,000 common shares on the same terms and conditions for up to 30 days after the date of the offering, July 14, 2011.

Delcath received proceeds, net of offering expenses and underwriting discounts and commissions, of approximately $23.5 million.  The Company intends to use the net proceeds from the sale of the shares for general corporate purposes, including, but not limited to, commercialization of its products, obtaining regulatory approvals, funding of its clinical trials, capital expenditures and working capital.

The offering was made pursuant to an effective shelf registration statement. Before you invest, you should read the base prospectus in such shelf registration statement, the prospectus supplement, when available, and other documents the Company has filed with the Securities and Exchange Commission for more complete information about the Company and this offering. The offering may be made only by means of a prospectus supplement and the accompanying prospectus, copies of which may be obtained by sending a request to the offices of Jefferies & Company, Inc., Attention: Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022 or at (888) 449-2342. Alternatively, you may get these documents for free by visiting EDGAR on the SEC website at http://www.sec.gov/.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any of the securities, nor shall there be any sale of these securities, in
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
9. Delcath Systems, Inc. Completes Phase III Study Enrollment
10. Delcath Systems Begins Data Analysis of Phase III Trial
11. Delcath Systems, Inc. to Present at the 12th Annual Needham Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... HILL, N.C. , April 17, 2015 /PRNewswire/ ... the creation of many new forms of provider ... Accountable Care Organizations (ACOs). The rapid evolution of ... to adapt their access, pricing and service delivery ... networks. To help the pharma sector ...
(Date:4/17/2015)... , April 17, 2015 Inivata, ... company announced today that their presence at the 2015 American ... a presentation by co-founder Nitzan Rosenfeld and a ... attending April 18 th - 22 nd . ... plasma using ctDNA , forms part of a ...
(Date:4/17/2015)... 17, 2015 Research and Markets ( ... "ADME-Toxicology Testing - Global Strategic Business Report" report ... worldwide markets for ADME-Toxicology Testing in US$ Million by ... ADME Testing. The report provides separate comprehensive ... Japan , Europe ...
Breaking Medicine Technology:Pharmaceutical Industry Struggling to Better Serve Provider Networks Such as Accountable Care Organizations (ACOs) 2Inivata Co-founder Nitzan Rosenfeld to Present at AACR Annual Meeting 2ADME-Toxicology Testing (In-Vivo, & In-Vitro) Market - Global Strategic Business Report 2015: Pharma Industry Renews Focus on Cost Optimization 2
... with Teplizumab Manufactured at ... MacroGenics, ROCKVILLE, ... actively enrolling adults and children ages,8 to 35 with recent-onset type 1 ... of three teplizumab dosing,regimens administered at the start of the study and ...
... and Oncomine Concepts Map Integral in Expression and Association ... ... Building on an earlier study,that used Oncomine(TM) to identify ETS-fusion proteins in ... of,four additional classes of ETS rearrangements in prostate cancer, each of,which activates ...
Cached Medicine Technology:MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus 2MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus 3MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus 4Gene Fusion Subtypes in Prostate Carcinoma Have Clinical Implications 2
(Date:4/18/2015)... Carinsurancesavings.biz has released a new blog post ... during Spring. , Spring can be a great ... make sure they compare the newest policies before deciding ... more about Spring car insurance offers by reading the ... are becoming more and more popular. Many insurance brokerage ...
(Date:4/18/2015)... April 18, 2015 Review of Ophthalmology ... a ‘Strategies for Success’ program for cataract surgeons attending ... in San Diego, where eye surgeon Jeffrey L. Martin, ... invitation-only event. Dr. Martin is the Managing Partner of ... Ophthalmology chose Dr. Martin to lead this year’s discussion ...
(Date:4/18/2015)... Raleigh, NC (PRWEB) April 18, 2015 ... the risk of developing mesothelioma later in life, but ... ways from mesothelioma that is unrelated to radiation. Surviving ... study on its website. Click here to read ... and Australia compared the cases of 45 patients who ...
(Date:4/18/2015)... York, NY (PRWEB) April 18, 2015 On ... Internal Security Threat Report , which they say, “exposes a ... how many new malware variants were introduced in 2014 - ... took for Zero Day threats to be identified and patched ... it is abundantly clear that doing business in a digital ...
(Date:4/18/2015)... (PRWEB) April 18, 2015 French physician ... on food choices when he uttered, “Tell me what ... are.” Using food to cope with stress or sadness ... Queendom.com indicates otherwise. Data collected from their ... fall victim to emotional eating, but for different reasons. ...
Breaking Medicine News(10 mins):Health News:Auto Insurance Plans Are Cheaper During Spring! 2Health News:Dr. Jeffrey Martin Invited to Share Latest Breakthroughs in Cataract Care During Roundtable Discussion at National 2015 ASCRS Meeting In San Diego 2Health News:New Study Examines Relationship Between Radiation for Hematologic Cancers and Development of Mesothelioma, According to Surviving Mesothelioma 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 4Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 5Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 3Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 4Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 5Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 6
... began as research into how diabetics could possibly preserve ... the vision of children afflicted with retinoblastoma. Dolores ... was researching protein kinase C gamma in the lens ... fascinating turn when she discovered a correlation between the ...
... ... of the New Video Marketing Quiz. , ... (PRWEB) March 9, 2010 -- EyeView , the world’s leading video solution provider for performance ... March 10, 2010 at 10 am ET. The Video Marketing Quiz showcases some of ...
... ... tools for monitoring apoptosis in live mammals, an important biomarker in cancer studies. , ... Madison, WI (PRWEB) March 9, 2010 ... sensitive tools for monitoring apoptosis in live mammals, an important biomarker in cancer studies. Under ...
... ... ... ... ...
... , , ... ... ... ...
... soda when the price went up, study found , TUESDAY, ... increases, people consume less of it, a new study has found. ... young adults, aged 18 to 30, beginning in 1985 to 1986 ... 10 percent increase in price was associated with a 7 percent ...
Cached Medicine News:Health News:K-State professor finds link between low oxygen levels in body and cancer-aiding protein 2Health News:EyeView Launches Innovative Video Marketing Quiz 2Health News:EyeView Launches Innovative Video Marketing Quiz 3Health News:Promega - TOP srl Agreement Enables Live Animal Imaging for Cancer Studies 2Health News:Wanted: Indianapolis Customer Service Professionals 2Health News:Wanted: Indianapolis Customer Service Professionals 3Health News:Wanted: Indianapolis Customer Service Professionals 4Health News:Wanted: Indianapolis Customer Service Professionals 5Health News:World's First 3D Dance DVD Released! 2Health News:World's First 3D Dance DVD Released! 3Health News:Cost of Junk Food May Influence Consumption 2
The rotating stage assembly is designed to give the researcher maximum flexibility in the mounting of specimens. It can be turned to any horizontal and vertical angle via a ball joint mounting arran...
The glass knife adapter allows for the use of glass knives or ralph knives on the Vibratome. The adapter can be installed in place of the standard razor blade mounting device....
Inquire...
Inquire...
Medicine Products: